AstraZeneca Press release

ADVISORY COMMITTEE BRIEFING MATERIALS FOR MOTAVIZUMAB NDA AVAILABLE ON US FDA WEB SITE The US Food and Drug Administration (FDA) today posted briefing materials in advance of 2 June 2010 Antiviral Drugs Advisory Committee to discuss the approval of motavizumab for the prevention of serious respiratory syncytial virus (RSV) disease in high-risk infants. The briefing materials can be found on the FDA web site. In December 2009, AstraZeneca announced that MedImmune, its biologics unit, had filed its formal regulatory reply to a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA). MedImmune received the CRL asking for additional information regarding motavizumab on 25 November 2008. This email has been sent via AstraZeneca's email alert service. Update your email preferences, unsubscribe from this service or contact us.

Legal notice Privacy policy © 2010 AstraZeneca